NASDAQ:VERU - Veru Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.38 -0.01 (-0.72 %)
(As of 12/12/2018 02:21 AM ET)
Previous Close$1.39
Today's Range$1.38 - $1.43
52-Week Range$0.93 - $2.37
Volume39,700 shs
Average Volume120,084 shs
Market Capitalization$76.29 million
P/E Ratio-5.52
Dividend YieldN/A
Beta0.87
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
Previous Symbol
CUSIP31446210
Phone305-509-6897

Debt

Debt-to-Equity Ratio0.12
Current Ratio1.01
Quick Ratio0.80

Price-To-Earnings

Trailing P/E Ratio-5.52
Forward P/E Ratio-4.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.66 million
Price / Sales5.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.91 per share
Price / Book1.52

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-6,610,000.00
Net Margins-130.26%
Return on Equity-38.09%
Return on Assets-29.78%

Miscellaneous

Employees175
Outstanding Shares55,280,000
Market Cap$76.29 million
OptionableOptionable

Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) released its earnings results on Tuesday, August, 14th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business had revenue of $5.50 million for the quarter, compared to analyst estimates of $5.20 million. Veru had a negative net margin of 130.26% and a negative return on equity of 38.09%. View Veru's Earnings History.

When is Veru's next earnings date?

Veru is scheduled to release their next quarterly earnings announcement on Thursday, December 13th 2018. View Earnings Estimates for Veru.

What price target have analysts set for VERU?

3 Wall Street analysts have issued 1 year price targets for Veru's shares. Their predictions range from $5.00 to $10.00. On average, they expect Veru's stock price to reach $7.50 in the next year. This suggests a possible upside of 443.5% from the stock's current price. View Analyst Price Targets for Veru.

What is the consensus analysts' recommendation for Veru?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.

What are Wall Street analysts saying about Veru stock?

Here are some recent quotes from research analysts about Veru stock:
  • 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (10/17/2018)
  • 2. Maxim Group analysts commented, "Veru announced the company was awarded 75% of the South Africa female condom tender, or a total of 120M female condoms over three years. We view this news as a significant positive, as it will continue to help offset the R&D burn associated with the urology pipeline, which is where we see the most significant value and upside in Veru." (8/27/2018)
  • 3. HC Wainwright analysts commented, "Valuation methodology. Our price target is derived from a market value of the firm at $302M, which includes a discounted cash flow-based asset value of $313M for DRS, excluding $10.7M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS. Risks include, but are not limited to: (1) failure of FC2 or Tamsulosin DRS to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of Tamsulosin DRS in clinical trials; (3) clinical trial failures with other pipeline candidates; and (4) potential dilution risk." (8/15/2018)

Has Veru been receiving favorable news coverage?

News headlines about VERU stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Veru earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Veru's key competitors?

Who are Veru's key executives?

Veru's management team includes the folowing people:
  • Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)
  • Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
  • Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)
  • Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec.

Who are Veru's major shareholders?

Veru's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (2.58%), AWM Investment Company Inc. (1.81%), Dimensional Fund Advisors LP (0.19%), Hound Partners LLC (0.15%) and Renaissance Technologies LLC (0.14%). Company insiders that own Veru stock include Daniel Haines, David R Bethune, Elgar Peerschke, Georges Makhoul, Harry Fisch, Jesus Socorro, Lucy Lu, Mitchell Shuster Steiner and O B Parrish. View Institutional Ownership Trends for Veru.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Veru.

Which institutional investors are buying Veru stock?

VERU stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, AWM Investment Company Inc., Hound Partners LLC and Dimensional Fund Advisors LP. Company insiders that have bought Veru stock in the last two years include Daniel Haines, David R Bethune, Elgar Peerschke, Georges Makhoul, Harry Fisch, Jesus Socorro, Lucy Lu, Mitchell Shuster Steiner and O B Parrish. View Insider Buying and Selling for Veru.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $1.38.

How big of a company is Veru?

Veru has a market capitalization of $76.29 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe.

What is Veru's official website?

The official website for Veru is http://www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (NASDAQ VERU)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel